Seeking Alpha

The FDA lifts a clinical hold on Lpath's (LPTN.OB) iSONEP, an antibody the firm is developing to...

The FDA lifts a clinical hold on Lpath's (LPTN.OB) iSONEP, an antibody the firm is developing to treat wet AMD and possibly other eye disorders. The FDA placed the hold in January after finding that a contractor was not complying with its regulations, but Lpath has since replaced the supplier. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector